Welcome to our dedicated page for KINETA news (Ticker: KANT), a resource for investors and traders seeking the latest updates and insights on KINETA stock.
The KANT news page on Stock Titan provides an archive of public announcements and press releases related to Kineta, Inc., a clinical-stage biotechnology company that focused on developing novel immunotherapies in oncology. These news items document Kineta’s work on cancer immune resistance, its VISTA-101 clinical program for the VISTA blocking antibody KVA12123, and the company’s strategic and corporate developments over time.
Readers can find coverage of Kineta’s clinical updates, including reported progress from the Phase 1/2 VISTA-101 trial in advanced solid tumors, where KVA12123 was evaluated as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). News reports describe safety and tolerability observations, dose escalation milestones, and early signals such as stable disease or partial responses in certain cohorts, as presented at conferences like the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC).
The news record also includes corporate announcements, such as Kineta’s February 2024 restructuring to reduce expenses and preserve cash, the subsequent exclusivity and right of first offer agreement with TuHURA Biosciences, and the definitive merger agreement under which TuHURA agreed to acquire Kineta. Later releases from TuHURA describe stockholder approvals of the merger and, ultimately, the completion of the acquisition, with KVA12123 being renamed TBS-2025 within TuHURA’s pipeline.
For investors and researchers, this news archive offers historical context on Kineta’s evolution from an independent clinical-stage biotechnology company trading under the KANT ticker to a business that has been acquired by TuHURA Biosciences. Reviewing these articles can help users understand how the VISTA-targeted antibody program advanced, how strategic alternatives were pursued, and how the merger terms and closing were communicated to the market.
TuHURA Biosciences (NASDAQ:HURA) has successfully completed the acquisition of Kineta, Inc. (OTCPK:KANT), adding a Phase 2 ready VISTA inhibiting monoclonal antibody to its immuno-oncology pipeline. The acquired drug candidate, formerly known as KVA1213, has been renamed to TBS-2025.
The acquisition unlocks the fourth tranche of funds from a previously announced $12.5 million PIPE financing. TuHURA plans to initiate a Phase 2 randomized trial in the second half of 2025, investigating TBS-2025 in combination with a menin inhibitor for NPM1 mutated AML treatment.
The strategic acquisition provides synergies with TuHURA's antibody drug conjugate (ADC) technology. The company is exploring the possibility of conjugating TBS-2025 with Delta Opioid Receptor inhibitors to create a bi-functional, bi-specific ADC targeting myeloid derived suppressor cells in the tumor microenvironment.
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immune-oncology company, and Kineta (OTC Pink:KANT), a clinical-stage biotechnology company, announced that stockholders of both companies have approved their proposed merger. At TuHURA's Special Meeting, stockholders approved increasing authorized shares to 200 million and reincorporating in Delaware. The merger is expected to close upon satisfaction of remaining closing conditions.
Both companies specialize in developing novel immunotherapies in oncology, focusing on addressing cancer immune resistance. The final voting results will be reported in Current Reports on Form 8-K with the SEC.
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immune-oncology company, announced its participation in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025. CEO James A. Bianco will present the company overview, focusing on their IFx-Hu2.0 Phase 3 program and first-in-class bi-specific immune modulating ADCs and APCs targeting MDSCs.
The presentation will also cover Kineta's VISTA inhibiting monoclonal antibody program. TuHURA previously announced a definitive agreement to acquire Kineta (OTC Pink: KANT) on December 11, 2024, which includes rights to Kineta's KVA12123 antibody. The merger is expected to close in Q2 2025, subject to closing conditions.
TuHURA Biosciences (NASDAQ:HURA) and Kineta presented updated results from two clinical studies at the AACR Annual Meeting. The first study, VISTA-101, evaluated KVA12123 (anti-VISTA antibody) alone and with pembrolizumab in advanced solid tumors. At 1,000mg dose every two weeks, KVA12123 achieved >90% VISTA receptor occupancy with no dose-limiting toxicities across 41 total patients.
The second study focused on TuHURA's IFx-Hu2.0 in advanced melanoma patients who previously failed checkpoint inhibitor (CPI) therapy. Three out of four heavily pre-treated patients achieved durable anti-tumor responses when rechallenged with CPI after IFx-Hu2.0 treatment. The therapy demonstrated increased T cell and B cell production with only mild Grade 1 and 2 adverse events.
TuHURA plans to initiate a Phase 3 trial in Merkel cell carcinoma and expects to close its merger with Kineta in Q2 2025, which includes acquiring rights to KVA12123.
TuHURA Biosciences (NASDAQ:HURA) announced two abstracts accepted for poster presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase:
1. Initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, both as monotherapy and in combination with pembrolizumab for advanced solid tumors, presented by Kineta's CSO.
2. Mechanistic insights into IFx-Hu2.0 therapy responses in patients with prior anti-PD-1 therapy failure in advanced melanoma, presented by Moffitt Cancer Center scientists.
The company also referenced its previously announced definitive agreement from December 11, 2024, to acquire Kineta, including rights to KVA12123, through a merger expected to close in Q2 2025, subject to funding and other closing conditions.
TuHURA Biosciences (NASDAQ:HURA) has entered into a definitive merger agreement to acquire Kineta, Inc. (OTC PINK:KANT), gaining rights to Kineta's novel KVA12123 antibody. The acquisition adds a Phase 2 novel checkpoint inhibitor to TuHURA's pipeline, with plans for a Phase 2a/b trial in mutated NPM1 AML in 2025.
KVA12123 is a VISTA-blocking immunotherapy administered as a monoclonal antibody infusion every two weeks. It has completed enrollment in its monotherapy arm, demonstrating safety at 1000mg dose level, and is finishing combination therapy trials with KEYTRUDA®. The transaction, following a $5 million exclusivity fee paid in July 2024, is expected to close in Q1 2025.
Kineta (OTC Pink: KANT) provided updates on its VISTA101 Phase 1/2 clinical trial for KVA12123, an anti-VISTA monoclonal antibody. The trial evaluates KVA12123 both as monotherapy and in combination with Merck's KEYTRUDA® in advanced solid tumors. Key findings include: successful clearance of all six monotherapy dose levels and second of four combination cohorts, no dose limiting toxicities, and favorable safety profiles. In monotherapy, 13 of 19 evaluable patients showed stable disease. The combination therapy demonstrated promising results, including a partial response with 54% tumor reduction and a confirmed complete response in non-target lesions.
Kineta announced the completion of enrollment in the monotherapy cohorts of its Phase 1 VISTA-101 clinical trial evaluating KVA12123, a novel VISTA blocking immunotherapy, in patients with advanced solid tumors. The trial enrolled patients in 6-dose cohorts ranging from 3mg to 1000mg every two weeks, with no dose limiting toxicities or cytokine related adverse events observed.
The study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). Initial results reported earlier this year showed partial response and stable disease in combination cohorts and durable stable disease in monotherapy cohorts. Kineta aims to complete full enrollment before year-end and will present additional scientific data in 2024 at an upcoming scientific meeting.
Kineta, a clinical-stage biotech firm, announced its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, held November 6-10, 2024, in Houston, Texas and virtually. The poster, presented by Dr. Jason Henry on November 8, 2024, will reveal new clinical data from an ongoing Phase 1/2 trial of KVA12123, Kineta’s VISTA blocking immunotherapy, alone and with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. The presentation is scheduled for 9:00 A.M. – 7:00 P.M. Central Time at Exhibit Halls AB, George R. Brown Convention Center. Abstract titles are available on the SITC website, and posters will be accessible on Kineta’s website post-conference.
FAQ
What is the current stock price of KINETA (KANT)?
